136 results on '"M Nishino"'
Search Results
2. [Gallbladder carcinosarcoma associated with pancreaticobiliary maljunction with biliary dilation:a case report].
- Author
-
Watahiki M, Kaneko J, Kiuchi R, Suzuki D, Kosugi T, Kusama D, Tamakoshi H, Niwa T, Takinami M, Tsuji A, Nishino M, Takahashi Y, Jindo O, Fukazawa A, Sasada Y, Yamada T, and Sakaguchi T
- Subjects
- Humans, Female, Aged, Gallbladder Neoplasms diagnostic imaging, Gallbladder Neoplasms surgery, Carcinosarcoma diagnostic imaging, Carcinosarcoma surgery, Carcinosarcoma pathology, Pancreaticobiliary Maljunction diagnostic imaging
- Abstract
A 68-year-old female patient was referred to our hospital with acute cholangitis. Computed tomography revealed common bile duct dilatation, gallbladder fundal tumor, and gallbladder wall thickening attached to the tumor. Cholangiography revealed pancreaticobiliary maljunction with biliary dilation. The patient was diagnosed with pancreaticobiliary maljunction with biliary dilation and gallbladder cancer and underwent liver S4b+5 and bile duct resection and reconstruction. Pathological results revealed that the gallbladder fundal tumor included sarcoma, and the gallbladder wall thickening had adenocarcinoma;thus, the patient was diagnosed with gallbladder carcinosarcoma.
- Published
- 2024
- Full Text
- View/download PDF
3. [Gentle Method to Elevate Left Liver Lobe in Robot Assisted Gastrectomy].
- Author
-
Nishino M, Yoshikawa T, Ogawa R, Sakon R, Ishizu K, Wada T, Hayashi T, and Yamagata Y
- Subjects
- Humans, Silicone Elastomers, Liver surgery, Gastrectomy methods, Robotics, Laparoscopy methods, Subcutaneous Emphysema surgery
- Abstract
Robot-assisted gastrectomy with the Davinci XiTM has been performed in our department since August 2019. This technique requires elevation of the left liver lobe. In order to prevent perioperative liver injury and expansion of postoperative subcutaneous emphysema, we use a silicone disc(HAKKO MEDICAL Co., Ltd.)and thread to elevate the liver. After docking the Davinci system, we move the needle as follows:(ⅰ). left side peritoneum near the left triangular ligament, (ⅱ). silicone rubber(, ⅲ). center of crus(, ⅳ). silicone rubber(, ⅴ). hepatic cirrus, and(ⅵ). right side peritoneum. Both ends of the thread are guided out of the abdominal cavity from both hepatic circumflex by end-close, forming a V-shape with the center of crus at the bottom, which provides a stable and effective view of the liver. Fifty-three cases were performed after introduction of this elevation technique. Median AST and ALT on postoperative day 1 were 37(14-1,556)IU/L and 30(10- 1,676)IU/L, respectively, although small subcutaneous emphysema confined to the anterior chest and upper abdominal wall was observed in 2 patients(3.8%). No cases of extensive subcutaneous emphysema involving the neck or extremities were observed. This elevation technique protects the liver and may reduce the incidence of postoperative subcutaneous emphysema.
- Published
- 2023
4. [A Case of Esophageal Cancer with Multiple Lung Metastases Resected after Stent Placement and Chemotherapy].
- Author
-
Ogo T, Ishihara K, Nishino M, Inokuch M, and Sakurai U
- Subjects
- Male, Humans, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Fluorouracil, Cisplatin, Stents, Esophageal Neoplasms drug therapy, Esophageal Neoplasms surgery, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma drug therapy, Carcinoma, Squamous Cell surgery, Lung Neoplasms drug therapy, Lung Neoplasms surgery, Lung Neoplasms secondary
- Abstract
A 70-year-old man was diagnosed with middle and lower thoracic esophageal squamous cell carcinoma. A computed tomography(CT)scan revealed multiple pulmonary metastases. The clinical stage was T3N1M1, Stage Ⅳb. After esophageal stent placement was performed to alleviate strong stenotic symptoms, cisplatin/5-fluorouracil(CDDP/5-FU)therapy was introduced, and 8 courses were completed. Four additional courses of 5-FU monotherapy were then administered. Following systemic chemotherapy, CT scans showed no evidence of lung metastases. About a year after the initial treatment, the patient underwent a thoracoscopic esophagectomy. Postoperatively, he was followed up without treatment and has remained alive for 1 year and 4 months without any recurrence.
- Published
- 2023
5. [Small intestinal mucormycosis associated with acute myeloid leukemia: a case report].
- Author
-
Nishino M, Mizuno H, Yamada K, Kamiyamamoto S, and Saito K
- Subjects
- Male, Humans, Intestine, Small pathology, Mucormycosis complications, Mucormycosis diagnostic imaging, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute pathology, Intestinal Diseases complications, Intestinal Diseases diagnostic imaging, Ileus complications, Ileus pathology
- Abstract
The patient was a man in his 70s. During the treatment for acute myeloid leukemia, abdominal pain and bloody stools appeared. A diagnosis of small intestinal ileus was made by computed tomography scan. Treatment with an ileus tube did not improve his condition, and enteroscopy revealed the presence of ileal ulcers. Based on histological examination, small intestinal mucormycosis was suspected, and thus, antifungal drugs were administered. However, the patient developed perforated peritonitis and underwent small intestine resection. He was finally diagnosed with small intestinal mucormycosis with the help of the resected specimen. The gastrointestinal form of mucormycosis rarely occurs, and small intestinal lesions are very rare. Enteroscopy was helpful in its diagnosis and treatment.
- Published
- 2023
- Full Text
- View/download PDF
6. [JAPANESE TRANSLATION AND LINGUISTIC VALIDATION OF THE RECAP OF ATOPIC ECZEMA (RECAP)].
- Author
-
Itonaga T, Yanagida N, Nishino M, Sato S, Ohmatsu H, Otake N, Makita E, Fukuie T, Miura T, Chiyotanda M, Suzuki M, Manabe T, Koike Y, Futamura M, Nagao M, Ogata M, Takayama R, Sugiyama A, Kataoka Y, Ishiuji Y, Masuda K, Tanaka A, Nakahara T, Murota H, Saeki H, Katoh N, and Ebisawa M
- Subjects
- Adult, Humans, Child, Japan, Surveys and Questionnaires, Linguistics, Translations, Dermatitis, Atopic therapy
- Abstract
Background: The Recap of atopic eczema (RECAP), a new core outcome of the atopic dermatitis trial, was translated into Japanese and linguistically validated., Methods: Translation into Japanese was accomplished according to the ISPOR (International Society for Pharmacoeconomics and Outcome Research) guidelines and the basic guidelines for scale translation. The translation process included two forward translations, reconciliation with native English speakers, third-party back translation, cognitive debriefing, review and harmonization by the original authors. Twenty-seven atopic dermatitis and pediatric specialists from 21 centers in Japan participated in the translation process. Cognitive debriefing was conducted through face-to-face interviews using a think-aloud method with the interview guide including questions about comprehensibility, relevance, comprehensiveness, recall period and suggested improvements, based on the COSMIN methodology., Results: No linguistic or cultural problems were encountered in the translation into Japanese. Cognitive debriefings were conducted with 10 adult patients and 10 parents of pediatric patients. Some minor modifications were made following discussion and approval by the research team and the original authors. The Japanese version of RECAP was considered to be understandable, comprehensive and relevant for adult patients and families of pediatric patients., Conclusion: The Japanese version of the RECAP, which has been validated as linguistically equivalent to the original version, is now available. Further evaluation of the measurement properties is needed in the future.
- Published
- 2023
- Full Text
- View/download PDF
7. [A Case of Breast Cancer in the Elderly Localized in the Nipple].
- Author
-
Yanai A, Nishino M, Kojima S, Yamasaki J, Uda Y, Ohara S, Hamada T, Ohashi K, Nakao E, Murakami M, and Okada T
- Subjects
- Aged, 80 and over, Female, Humans, Mammography, Nipples surgery, Sentinel Lymph Node Biopsy, Breast Neoplasms surgery, Carcinoma, Ductal, Breast surgery
- Abstract
An 89-year-old woman presented to our clinic with a complaint of a wound in the left nipple. The pathological diagnosis via skin biopsy revealed adenocarcinoma. A physical examination, mammography, ultrasonography, and CT scan revealed a mass in the left nipple. However, a definite diagnosis could not be established by skin biopsy. Left breast-conserving surgery and sentinel lymph node biopsy were performed for diagnosis and treatment. Histological examination revealed a scirrhous type invasive ductal carcinoma in the left nipple and areola with skin invasion and lymph node metastasis. Radiation and hormone therapy were used as adjuvant therapy. She is alive with no local recurrence for 5 months post surgery. Since ductal carcinoma of the nipple is uncommon, we present this case report along with a review of the relevant literature.
- Published
- 2021
8. [Case report of a patient with recurrence after endoscopic submucosal dissection for superficial esophageal cancer, diagnosed with mediastinal lymph node endoscopic ultrasound-fine needle aspiration based on the symptom of hoarseness].
- Author
-
Takayama H, Komura T, Yoshio T, Yanagi M, Nishino M, Orita N, Nishikawa M, Kagaya T, Kawashima A, and Unoura M
- Subjects
- Aged, 80 and over, Biopsy, Fine-Needle, Endoscopic Ultrasound-Guided Fine Needle Aspiration adverse effects, Hoarseness etiology, Humans, Lymph Nodes, Male, Neoplasm Recurrence, Local, Endoscopic Mucosal Resection adverse effects, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms surgery
- Abstract
The patient was an 81-year-old man who presented with a complaint of hoarseness. When he was 80 years old, he had developed superficial esophageal cancer and had undergone endoscopic submucosal dissection (ESD) at our hospital. Two months after the ESD, he developed hoarseness. Computed tomography (CT) scan showed no abnormal findings at that time;therefore, he was diagnosed with idiopathic vocal cord paralysis, and followed up with symptom treatment in the Gastroenterology and Otolaryngology Departments. Ten months after the ESD, a CT scan revealed mediastinal lymph node swelling. He was admitted to our hospital for histopathological examination of the lymph node using endoscopic ultrasound-fine needle aspiration (EUS-FNA). The histopathological examination revealed squamous cell carcinoma of the lymph node, similar to the primary esophageal tumor. This result suggests that laryngeal nerve paralysis involving hoarseness is caused by lymph node metastasis of superficial esophageal cancer. We report that histopathological examination with EUS-FNA helps in determining the cause of hoarseness that develops after ESD.
- Published
- 2021
- Full Text
- View/download PDF
9. [A Case of Metastatic Colorectal Cancer with Hyperammonemic Encephalopathy Induced by mFOLFOX6 and SOX Therapy].
- Author
-
Murase H, Oono R, Yoshida T, Suzuki Y, Hayashi K, Nishino M, Irie T, Suzuki Y, Higuchi K, Baba H, Takahashi H, Yoshinouchi S, Ueda Y, Enjoji M, and Obata M
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Humans, Male, Neoplasm Recurrence, Local, Brain Diseases, Colonic Neoplasms drug therapy, Hyperammonemia chemically induced, Hyperammonemia drug therapy, Rectal Neoplasms drug therapy
- Abstract
A 77-year-old man was given a diagnosis of pT4aN0M1a(PUL2), stage Ⅳ, RAS mutant type, after the operation for advanced ascending colon cancer. He was administered mFOLFOX6 plus Bmab as first-line chemotherapy. He showed consciousness disturbance on the 2nd day during the 6 cycles. Because of head computed tomography and magnetic resonance imaging showing no abnormal findings, we diagnosed convulsive seizure. His consciousness level gradually improved after intravenous infusion. He showed consciousness disturbance on the 2nd day during the 7 cycles again. Because blood ammonia level were high at 400μg/dL, he was diagnosed as hyperammonemic encephalopathy. His consciousness level rapidly recovered after branched chain amino acid(BCAA)infusion. SOX plus Bmab therapy was started as a post-treatment, he developed hyperammonemia(NH3 288μg/dL)again, on the 4th day during the 3 cycles. After taking of oral administration of BCAA and lactulose, the recurrence of hyperammonemic encephalopathy was not found. Therefore, 3 cycles of SOX plus Bmab therapy and 12 cycles of IRIS plus Bmab therapy were administered.
- Published
- 2020
10. [Cancer of the Ascending Colon Diagnosed at the Same Time as Breast Cancer Following Leukemia Treatment for Which Laparoscopic Surgery Was Performed-A Case Report].
- Author
-
Yamazaki J, Hamada T, Uda Y, Ohara S, Kojima S, Nishino M, Kuroda N, Tanaka N, Imado K, Mori A, Shimizu Y, Matsuo S, and Tsukamoto Y
- Subjects
- Aged, 80 and over, Colon, Ascending, Female, Humans, Mastectomy, Breast Neoplasms diagnosis, Breast Neoplasms surgery, Colonic Neoplasms diagnosis, Laparoscopy, Leukemia drug therapy, Neoplasms, Multiple Primary diagnosis
- Abstract
An 83-year-old woman received 8 courses of chemotherapy(mogamulizumab)for adult T cell leukemia in the hematolo- gy department of our hospital, after which she achieved complete remission and was followed up with chemotherapy(VP/ MST: sobuzoxane/etoposide)as an outpatient. Later, diarrheal symptoms appeared, and detailed examinations led to a diagnosis of cancer of the ascending colon. Although no distal metastasis was found, breast cancer was also revealed in the C area of the right breast. The general status of the patient was favorable; thus, right pectoral muscle-conserving mastectomy and concomitant sentinel lymph node biopsy were performed through laparoscope-assisted extended right hemicolectomy. The postoperative course was favorable, and she was discharged on hospital day 7. The excised tumors were pathologically diagnosed as stageⅠ breast cancer and stage Ⅲa colorectal cancer. Chemotherapy(VP/MST)was administered without adjuvant chemotherapy. Presently, 18 months after surgery, complete remission of adult T cell leukemia has been maintained, without metastasis and recurrence of cancer of the ascending colon and breast cancer.
- Published
- 2019
11. [A Case of Esophageal Cancer with Aortic Thrombosis That Was Successfully Treated by Aortic Thrombectomy and Video-Assisted Thoracoscopic Esophagectomy].
- Author
-
Kawada J, Nishino M, Hata M, Tanizaki K, Hayashi Y, Okano M, Nagai K, Kim Y, Motoori M, Okuyama M, Funatsu T, Fujitani K, Tsujinaka T, and Imamoto H
- Subjects
- Aged, Humans, Male, Neoplasm Recurrence, Local, Thrombectomy, Esophageal Neoplasms complications, Esophageal Neoplasms surgery, Esophagectomy, Thrombosis etiology, Thrombosis surgery
- Abstract
We report a case of esophageal cancer with aortic thrombosis that occurred during chemotherapy and was successfully treated by aortic thrombectomy and video-assisted thoracoscopic esophagectomy. A 70-year-old man with esophageal cancer( Mt, Type 1c, cT2cN0cM0, cStage Ⅱ)was administered 5-FU plus cisplatin chemotherapy. On day 7 in the first course of the chemotherapy, he experienced abdominal pain. Abdominal CT revealed endo-aortic thrombotic deposits in the aortic arch about 3 cm in diameter. He immediately received heparin at a dose of 20,000 U/day administered intravenously, but the thrombus had not resolved by the next day. He underwent aortic thrombectomy, and warfarin was administered orally after the thrombectomy. He did not experience any difficulties or discomfort related to the thrombus after the thrombectomy. He then underwent video-assisted thoracoscopic esophagectomy and was discharged uneventfully on the 18th postoperative day. Currently, he is under follow-up with no recurrence.
- Published
- 2019
12. [A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy].
- Author
-
Kawada J, Nishino M, Hata M, Tanizaki K, Ogino T, Hoshino H, Okano M, Nagai K, Kim Y, Okuyama M, Tsujinaka T, and Imamoto H
- Subjects
- Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drug Combinations, Female, Humans, Neoplasm Recurrence, Local, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Oxonic Acid therapeutic use, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Tegafur therapeutic use
- Abstract
We report a case of recurrent gastric cancer that was successfully treated by S-1 chemotherapy.An 81-year-old woman with advanced gastric cancer[L Less, Type 2, cT4a(SE), cN0H0P0M0, cStageⅡB]underwent distal gastrectomy.Abdominal CT performed 6 months after surgery revealed a low-density area in the liver.She was diagnosed with liver metastasis and started receiving S-1 chemotherapy.The liver metastasis achieved complete response, so S-1 chemotherapy was discontinued 12 months after recurrence.Abdominal CT performed 9 months after the discontinuation of S-1 chemotherapy revealed multiple low-density areas in the liver.She started receiving S-1 chemotherapy again, but S-1 chemotherapy was discontinued because of side effects after 2 courses.The patient died 24 months after receiving S-1 chemotherapy.
- Published
- 2019
13. [Analysis of Patients Who Received Nutritional Support and the Enhanced Recovery after Surgery(ERAS)Protocol after Esophagectomy].
- Author
-
Kawada J, Nishino M, Hata T, Tanizaki K, Ogino T, Hoshino H, Okano M, Nagai K, Kim Y, Okuyama M, Tsujinaka T, and Imamoto H
- Subjects
- Aged, Esophageal Neoplasms surgery, Female, Humans, Male, Middle Aged, Nutrition Assessment, Postoperative Period, Retrospective Studies, Esophagectomy, Nutritional Support
- Abstract
Background: Malnutrition is a frequently observed phenomenon in patients with esophageal cancer after esophagectomy. Nutritional support and the enhanced recovery after surgery(ERAS)protocol may prevent malnutrition., Method: Nine patients who underwent esophagectomy for esophageal cancer received perioperative management according to the ERAS protocol and enteral nutrition support(ELENTAL®or ENEVO®). We retrospectively evaluated the efficacy and safety of our perioperative management., Results: The median day of first oral intake(water)was the second postoperative day. The median day of first oral intake(food)was the seventh postoperative day. The patients could consume more than one and a half bottle of enteral nutrition for a year after surgery. The prognostic nutritional index(PNI)was higher than 40, and the neutrophil-to-lymphocyte ratio(NLR)was lower than 3 for a year after surgery., Conclusions: Perioperative management according to the ERAS protocol and enteral nutrition support(ELENTAL®or ENEVO®)might be feasible and prevent malnutrition in patients after esophagectomy.
- Published
- 2018
14. [A Case of Effective Palliative Care with CART for Refractory Ascites Associated with Cancerous Peritonitis of Gastric Cancer].
- Author
-
Kawada J, Nishino M, Hata T, Ogino T, Hoshino H, Okano M, Nagai K, Kim Y, Okuyama M, and Tsujinaka T
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Ascites etiology, Ascitic Fluid, Cell-Free System, Drainage, Humans, Male, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Ascites therapy, Palliative Care, Peritonitis complications, Stomach Neoplasms complications
- Abstract
Refractory ascites associated with cancerous peritonitis causes abdominal tension and reduced oral intake. Frequent ascites drainage can cause rapid worsening ofa patient's general condition. Cell-free and concentrated ascites reinfusion therapy (CART)for refractory ascites was first covered in 1981, and the general conditions ofpatients and their symptoms could be improved after undergoing CART. Herein, we report a case of effective palliative care with CART for refractory ascites associated with cancerous peritonitis. A 66-year-old man was admitted to our hospital because ofabdominal distension. Computed tomography revealed the presence ofascites and gastric wall thickness; upper gastrointestinal endoscopy revealed an ulcerated lesion with raised margins on the body ofthe stomach. Biopsy ofthis lesion confirmed the diagnosis ofadenocarcinoma, and he was diagnosed with gastric cancer(M, Type 3, cT4a[SE], cN0, cH0, cP1, cM1, cStage IV). He underwent palliative care for ascites, followed by FLTAX regimen chemotherapy(5-fluorouracil[5-FU]and Leucovorin[LV]combined with weekly paclitaxel[PTX]). He received CART for 8 courses without complications, and his symptoms improved after receiving CART. He survived for about 18 months, and could ingest a normal diet for a long time. CART may be favorable in palliative care for massive ascites associated with cancerous peritonitis.
- Published
- 2018
15. [A Case of Advanced Esophageal Cancer Successfully Treated with Multidisciplinary Therapy].
- Author
-
Kawada J, Nishino M, Hata T, Ogino T, Okawa M, Hoshino H, Okano M, Nagai K, Kakita N, Kim Y, Okuyama M, and Tsujinaka T
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Esophageal Neoplasms pathology, Humans, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Treatment Outcome, Esophageal Neoplasms therapy
- Abstract
We report a case of advanced esophageal cancer that was successfully treated using chemotherapy, operation, and chemoradiotherapy. A 66-year-old man with advanced esophageal cancer(Mt, O-Is, T4[N0.7-stomach], N2, M0, Stage III)was administered chemotherapy(docetaxel[DOC], cisplatin[CDDP], and 5-fluorouracil[5-FU]: DCF). As the esophageal tumor achieved complete clinical response after 2 courses of chemotherapy, lymph node dissection and proximal gastrectomy were performed for the residual tumor. Abdominal CT 3 months after surgery revealed lymph node swelling. He was diagnosed with lymph node metastasis and was administered chemoradiotherapy. After chemoradiotherapy, liver metastasis was revealed, and he underwent immune checkpoint inhibitor immunotherapy. Despite the administration of immune checkpoint inhibitors, the liver metastasis developed, so he was treated with S-1 chemotherapy. S-1 chemotherapy resulted in a favorable response, and almost all metastatic lesions decreased. The patient is alive 12 months after S-1 chemotherapy without any signs of tumor regrowth.
- Published
- 2018
16. [A Case of Resected Superior Sulcus Tumor with Pathological Complete Response after Trimodality Therapy].
- Author
-
Nishino M, Tomizawa K, Ohara S, Fujino T, Sesumi Y, Koga T, Sato K, Kobayashi Y, Chiba M, Shimoji M, Takemoto T, and Mitsudomi T
- Subjects
- Aged, Carcinoma, Squamous Cell diagnostic imaging, Female, Humans, Lung Neoplasms pathology, Pneumonectomy, Treatment Outcome, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Lung Neoplasms diagnostic imaging, Lung Neoplasms therapy
- Abstract
The current case was 73-year-oldwoman. She was referredto our hospital for an abnormal shadow of chest X-ray in the upper right lung field. Chest CT showed 3.5 cm of tumor located at the apex of right lobe with invasion of the chest wall. The tumor was diagnosed as squamous cell carcinoma using CT guided needle biopsy(superior sulcus tumor, clinical T3N0M0, Stage II B). The neoadjuvant therapy, 4 courses of chemotherapy(CBDCA plus PTX)andconcurrent radiotherapy(45 Gy/25 Fr)was performed. Chest CT revealed that tumor size was decreased to 2.3 cm in a diameter, and therapeutic effect was decided as partial response(34%). Upper right lobectomy combinedwith the chest wall(1th to 3th ribs)andmed iastinal lymph node dissection were performed. The pathological specimens showed no residual cancer cells(Ef3, pathological complete response[pCR]). She discharged without complications at 10 days after surgery. It is important to collect cases which obtainedpCR for development of more effective preoperative therapy.
- Published
- 2018
17. [Analysis of Patients Who Received Enteral Nutrition in the Course of Chemotherapy].
- Author
-
Kawada J, Nishino M, Hata T, Ogino T, Hoshino H, Okano M, Nagai K, Kim Y, Okuyama M, and Tsujinaka T
- Subjects
- Aged, Female, Humans, Male, Antineoplastic Agents adverse effects, Enteral Nutrition, Stomach Neoplasms drug therapy
- Abstract
Background: Chemotherapy-related adverse events can deteriorate the quality of life, as well as chemotherapy tolerance, for patients with gastric cancer. Nutritional support may prevent chemotherapy-related adverse events., Methods: Five patients who received chemotherapy for advanced gastric cancer were prescribed enteral nutrition(Elental®or ENEVO®). We retrospectively evaluated the efficacy and safety of chemotherapy while receiving enteral nutrition., Results: All patients consumed more than one bottle of enteral nutrition during chemotherapy. Median progression-free survival(PFS)and overall survival(OS)were 166 days(100-349)and 328 days(115-431), respectively. Major Grade 3 or 4 adverse events included neutropenia(0%), anemia(40%), and diarrhea(20%). The prognostic nutritional index(PNI)was higher than 40, and the neutrophil lymphocyte ratio(NLR)was lower than 3 over the course of chemotherapy., Conclusions: Nutritional support for gastric cancer patients receiving chemotherapy is feasible. There was a low incidence of chemotherapy-related hematological toxicity, with a relatively longer PFS in patients receiving enteral nutrition.
- Published
- 2017
18. [A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
- Author
-
Kim Y, Hoshino H, Kakita N, Yamasaki M, Hosoda Y, Nishino M, Okano M, Kawada J, Okuyama M, and Tsujinaka T
- Subjects
- Aged, Albumins administration & dosage, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Humans, Neoplasm Invasiveness, Paclitaxel administration & dosage, Pancreatectomy, Pancreatic Neoplasms blood supply, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Gemcitabine, Celiac Artery surgery, Neoadjuvant Therapy, Pancreatic Neoplasms drug therapy
- Abstract
A 70-year-old woman with locally advanced pancreatic body cancer invading the celiac axis underwent 4 courses of preoperative chemotherapy consisting of gemcitabine(GEM)plus nab-paclitaxel(nab-PTX)on days 1, 8, and 15 every 4 weeks, followed by radiation therapy(CRT; 50.4Gy delivered in 28 daily fractions). The tumor size was greatly diminished and levels of all tumor markers were decreased. R0resection by distal pancreatectomy with en bloc celiac axis resection(DP-CAR)was performed. The histopathologic findings showed that the effect of CRT was grade 2b(Evans' classification), and the surgical margins were histologically clear. After the surgery, S-1 was administered continuously. The patient shows no signs of recurrence 1 year after surgery.
- Published
- 2016
19. [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
- Author
-
Kawada J, Nishino M, Hosoda Y, Hoshino H, Okano M, Nagai K, Okuyama M, Kim Y, and Tsujinaka T
- Subjects
- Aged, Ascites etiology, Female, Fluorouracil administration & dosage, Humans, Leucovorin administration & dosage, Male, Middle Aged, Neoplasm Metastasis, Paclitaxel administration & dosage, Retrospective Studies, Stomach Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Purpose: Advanced gastric cancer patients with malignant ascites cannot tolerate S-1 plus cisplatin-containing therapy. The good toxicity profile of the FLTAX regimen(5-fluorouracil[5-FU]and Leucovorin[l-LV]combined with weekly paclitaxel) might make it a viable alternative treatment for these patients. We retrospectively evaluated the efficacy and safety of FLTAX in advanced gastric cancer patients., Materials and Methods: Patients with advanced gastric cancer with malignant ascites were treated with 60mg/m2 paclitaxel, followed by 500 mg/m2 5-FU and 250 mg/m2 l-LV on days 1, 8, and 15. Treatment courses were repeated every 28 days. Patients were treated in our hospital from 2014 to 2016., Results: Three advanced gastric cancer patients with malignant ascites received the FLTAX regimen. The median age was 66 years(range 58-66). The median number of treatment courses was 2(range 1-20). The median progression-free survival and overall survival were 55(95%CI 24-.)and 272(95%CI 108-.)days, respectively. Observed Grade 3-4 adverse events were as follows: hyponatremia(1), anorexia(1), upper gastrointestinal hemorrhage(1), and thromboembolic event(1). No treatment-related death occurred., Conclusion: FLTAX demonstrated an acceptable toxicity profile, and may be a good option for gastric cancer patients with malignant ascites.
- Published
- 2016
20. [A Case of Large Rectal Villous Adenoma Associated with Tenesmus and Body Weight Loss].
- Author
-
Okano M, Okuyama M, Nishino M, Hoshino H, Kawada J, Kim Y, and Tsujinaka T
- Subjects
- Aged, Colectomy, Colonoscopy, Humans, Male, Rectal Neoplasms surgery, Adenoma, Villous complications, Adenoma, Villous surgery, Rectal Neoplasms pathology, Weight Loss
- Abstract
The patient was a 78-year-old man who was hospitalized with a 1-month history of tenesmus and body weight loss. Blood tests revealed a mild increase in tumor markers(CEA 9.7 ng/mL)and an elevation of the inflammatory response. Colonoscopic examination disclosed a full circular lateral spreading tumor(LST)extending from the second Houston valve to the rectosigmoidal region with a more than 10 cm length. Since invasion to the SM layer was suspected, endoscopic resection was judged inapplicable and laparoscopic low anterior resection with D2 lymph node dissection was performed, along with covering ileostomy. The final pathology diagnosis was villous adenoma with carcinoma in adenoma, showing multiple villous structures categorized as high dysplasia. Postoperatively, he was free from tenesmus and his body weight increased. In addition, normalization of the tumor markers occurred.
- Published
- 2016
21. [A Case of Laparoscopic Resection of a Lymph Node Recurrence after Surgery for Descending Colon Cancer].
- Author
-
Okano M, Okuyama M, Nishino M, Hoshino H, Kawada J, Kim Y, and Tsujinaka T
- Subjects
- Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab administration & dosage, Capecitabine administration & dosage, Colon, Descending surgery, Colonic Neoplasms drug therapy, Colonic Neoplasms pathology, Combined Modality Therapy, Female, Humans, Lymph Node Excision, Lymph Nodes surgery, Lymphatic Metastasis, Recurrence, Colon, Descending pathology, Colonic Neoplasms surgery, Laparoscopy, Lymph Nodes pathology
- Abstract
The patient was an 81-year-old woman who underwent laparoscopic anterior resection for her descending colon cancer with final pathology results of tub2, pT3(SS), int, INFb, ly0, v1, EX(-), no lymph metastasis, and fStage II . She was followed up without adjuvant chemotherapy. Six months after the surgery, a CT scan revealed a tumor shadow 8mm in diameter near the clip fixed around the inferior mesenteric vein(IMV). After another 3 months, the tumor size increased to 11mm and it was diagnosed as a recurrence. Chemotherapy with capecitabine and bevacizumab was carried out for 6 months. Since her treatment response was judged as PR and no other recurrence was found, a local resection was planned. In order to identify the exact location of the recurrent lesion, a small laparotomy was performed at first to identify the tumor via palpation. A laparoscopic surgery was then performed to remove the recurrent lesion. Based on a pathological examination, the tumor was diagnosed as a lymph node recurrence and the histological response was judged as Grade 1b. A laparoscopic approach is technically feasible even for resection of recurrent lesions.
- Published
- 2016
22. [A Case of Splenic-Hilum Lymph Node Recurrence after Spleen Preserving Total Gastrectomy for Gastric Cancer Following Neoadjuvant Chemotherapy].
- Author
-
Nishino M, Okano M, Hoshino H, Kawada J, Okuyama M, Kim Y, and Tsujinaka T
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Gastrectomy, Hepatectomy, Humans, Liver Neoplasms drug therapy, Liver Neoplasms secondary, Liver Neoplasms surgery, Lymphatic Metastasis, Male, Recurrence, Stomach Neoplasms drug therapy, Stomach Neoplasms surgery, Neoadjuvant Therapy, Spleen pathology, Stomach Neoplasms pathology
- Abstract
A 69-year-old man was diagnosed with a large type 3, cT4bN2M0, cStage III c advanced gastric cancer located at the lesser curvature of the upper stomach. Neoadjuvant chemotherapy with S-1 plus CDDP was administered, and partial response was obtained after 2 courses. Subsequently, spleen preserving total gastrectomy with partial hepatectomy was performed. The final pathological diagnosis was UM, Less, yType 3, por1, ypT4b(SI liver), was ly2, v1, ypN2, M0, pStage III c, R0. Adjuvant chemotherapy with S-1 was administered; however, 5 months after the surgery, splenic-hilum lymph node recurrence was detected. Chemotherapy with CPT-11 plus CDDP was administered and a salvage operation was planned when the response to treatment was nonCR or nonPD. After 6 courses of chemotherapy, the treatment response was PR. Nine months after the first operation, spleno-pancreatic tail resection combined with partial hepatectomy was performed. The patient is currently disease-free without chemotherapy.
- Published
- 2016
23. [Analysis of Short-Term Outcomes after Laparoscopy-Assisted Pylorus-Preserving Gastrectomy].
- Author
-
Kawada J, Nishino M, Hosoda Y, Hoshino H, Okano M, Nagai K, Okuyama M, Kim Y, and Tsujinaka T
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Postoperative Complications, Retrospective Studies, Treatment Outcome, Gastrectomy, Laparoscopy methods, Stomach Neoplasms surgery
- Abstract
Background: Pylorus-preserving gastrectomy(PPG)has long been used for the treatment of early gastric cancer, and its survival benefits, postoperative symptoms, and functional outcomes have already been reported in several studies. This study aimed to evaluate the short-term outcomes after LAPPG in our hospital., Methods: Ten patients with early gastric cancer underwent LAPPG from 2013 to 2015 in our hospital. Their short-term outcomes after LAPPG were retrospectively analyzed., Results: No intraoperative complications were observed, and no patient required conversion to open surgery or reoperation. At 1 year after the operation, the relative body weight(present/preoperative)of the patients was 94.8%, and the incidence of nausea, diarrhea, abdominal fullness, and vomiting was, each, 1 in 7., Conclusion: The short-term results show that LAPPG seems to be beneficial in terms of postoperative symptoms and functional outcomes.
- Published
- 2016
24. [A Case of Laparoscopic Transhiatal Esophagectomy for Esophageal Cancer after Chemoradiotherapy].
- Author
-
Kawada J, Nishino M, Hosoda Y, Hoshino H, Okano M, Nagai K, Okuyama M, Kim Y, and Tsujinaka T
- Subjects
- Aged, Chemoradiotherapy, Deglutition Disorders etiology, Esophageal Neoplasms complications, Esophagectomy, Humans, Laparoscopy, Male, Treatment Outcome, Esophageal Neoplasms therapy
- Abstract
Patients with esophageal cancer often have various comorbidities, and these sometimes limit treatment choices. We report a case of esophageal cancer surgically treated using laparoscopic transhiatal esophagectomy after chemoradiotherapy in an elderly man with interstitial lung disease. A 77-year-old man who had undergone upper gastrointestinal endoscopic examination was admitted to our hospital with a diagnosis of esophageal cancer and interstitial lung disease. We diagnosed T4 esophageal cancer, and administered chemoradiotherapy. The chemoradiotherapy reduced the size of the tumor, but an esophageal stricture remained. A non-transthoracic approach was thought to be an appropriate choice for a patient at high risk for postoperative respiratory complications. Laparoscopic transhiatal esophagectomy was performed safely and successfully. In the postoperative course, temporary tracheotomy was necessary, but the tracheotomy tube was ultimately removed, after which he was able to consume food.
- Published
- 2016
25. [Hepatic Resection of Multiple Liver Metastases from Gastric Cancer after Molecular Targeted Chemotherapy(S-1 plus Cisplatin plus Trastuzumab)].
- Author
-
Kim Y, Hosoda Y, Nishino M, Okano M, Kawada J, Yamasaki M, Nagai K, Yasui M, Okuyama M, and Tsujinaka T
- Subjects
- Cisplatin administration & dosage, Drug Combinations, Gastrectomy, Hepatectomy, Humans, Liver Neoplasms secondary, Liver Neoplasms surgery, Lymph Node Excision, Lymphatic Metastasis, Male, Middle Aged, Molecular Targeted Therapy, Oxonic Acid administration & dosage, Recurrence, Stomach Neoplasms surgery, Tegafur administration & dosage, Trastuzumab administration & dosage, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Liver Neoplasms drug therapy, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology
- Abstract
A 62-year-old man was diagnosed with gastric cancer and underwent distal gastrectomy, and D1+b lymph node dissection. He was diagnosed postoperatively with T1b (sm2) N0M0, StageⅠA gastric adenocarcinoma and did not receive any adjuvant chemotherapy after surgery. One year and 6 months after gastrectomy, blood analysis indicated high levels of carcinoembryonic antigen (CEA 262.1 ng/mL) while abdominal computed tomography (CT) revealed multiple liver tumors (S7: 15 mm, S7/8: 20 mm). The patient was diagnosed with metachronous multiple liver metastases from gastric cancer. Chemotherapy, combined with molecular targeted therapy (S-1 plus cisplatin [CDDP] plus trastuzumab), was administered because of overexpression of the human epidermal growth factor receptor 2 (HER2) protein in the primary tumor as assessed by immunohistochemistry, the CEA levels decreased immediately after 2 cycles of the chemotherapy, and the liver metastases shrank markedly with no evidence of new lesions on abdominal CT. However, after treatment, Grade 3 neutropenia and diarrhea were observed. Chemotherapy was suspended and hepatic resection was performed. After hepatic resection, the liver tumors were histologically evaluated as Grade 2 metastatic gastric adenocarcinoma, and the HER2 expression of remnant carcinoma cells was established. The patient has been in good health and remained free of recurrences in the 2 years and 3 months after the liver resection. Surgery with preoperative chemotherapy (S-1 plus CDDP plus trastuzumab) can be an effective treatment for liver metastasis from HER2-positive gastric cancer.
- Published
- 2015
26. [A Case of HER2-Positive Advanced Gastric Cancer with a Pathological Complete Response to Neoadjuvant Chemotherapy with S-1/CDDP/Trastuzumab].
- Author
-
Nishino M, Hosoda Y, Okano M, Nagai K, Yasui M, Kim Y, and Tsujinaka T
- Subjects
- Adenocarcinoma chemistry, Adenocarcinoma surgery, Cisplatin administration & dosage, Drug Combinations, Gastrectomy, Humans, Lymphatic Metastasis, Male, Middle Aged, Oxonic Acid administration & dosage, Receptor, ErbB-2 analysis, Stomach Neoplasms chemistry, Stomach Neoplasms pathology, Stomach Neoplasms surgery, Tegafur administration & dosage, Trastuzumab administration & dosage, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy, Stomach Neoplasms drug therapy
- Abstract
A 61-year-old man was referred to our hospital because of epigastric pain. Upper gastrointestinal endoscopy revealed a type 2 tumor at the gastric antrum, which was diagnosed as gastric adenocarcinoma (tub1) by pathological examination and was HER2 positive 3+ by the IHC method. Abdominal computed tomography revealed multiple metastases to regional lymph nodes (LNs), including bulky nodes at No. 3, 6, and 11p stations. In particular, No. 6 LN was 43 mm in diameter and had invaded to the pancreas. The clinical stage was Ⅲc (T4aN3M0) and neoadjuvant chemotherapy was conducted using S-1/CDDP/trastuzumab. After 2 cycles of chemotherapy, a partial clinical response was obtained and distal gastrectomy with LN dissection (D2 plus No. 16 LN) was performed. The pathological specimens showed no residual cancer cells in the stomach and LNs (Grade 3: pCR). Adjuvant chemotherapy was not administered. The patient is alive 10 months after the surgery with no evidence of recurrence.
- Published
- 2015
27. [A Case of Bladder Adenocarcinoma with Rectal Metastasis].
- Author
-
Okano M, Yasui M, Nishino M, Hosoda Y, Kawada J, Nagai K, Kim Y, Okuyama M, and Tsujinaka T
- Subjects
- Adenocarcinoma secondary, Aged, Biopsy, Humans, Lung Neoplasms secondary, Male, Neoplasm Invasiveness, Rectal Neoplasms secondary, Recurrence, Urinary Bladder Neoplasms pathology, Adenocarcinoma surgery, Rectal Neoplasms surgery, Urinary Bladder Neoplasms surgery
- Abstract
A 77 year-old man with asymptomatic microscopic hematuria underwent a cystoscopic examination, which identified a broad-based papillary tumor at the cervix of the bladder. Adenocarcinoma was detected in the biopsy specimen. MRI and CT examination showed a huge papillary tumor of the bladder invading the inner lobe of the prostate. In addition, the wall of the lower rectum exhibited thickening with enlargement of the regional lymph nodes. Endoscopy disclosed a hemi-circular rectal tumor and pathological examination revealed adenocarcinoma, the profile of which was similar to the bladder tumor. The levels of CEA and CA19-9 were 5.3 ng/mL and 39 U/mL, respectively. A differential diagnosis considering bladder cancer, rectal cancer, or both was necessary before planning a treatment strategy. Since both tumors were judged to be resectable, total pelvic exenteration was carried out. Through detailed postoperative pathological examinations, it was concluded that this tumor was of bladder origin and it invaded the prostate along with metastasis to the rectum. Adenocarcinoma of the bladder is extremely rare and exhibits aggressive behavior.
- Published
- 2015
28. [A Case of Conversion Surgery after Long-Term Chemotherapy for Advanced Gastric Carcinoma with Synchronous Distant Metastasis].
- Author
-
Nagai K, Tsujinaka T, Nishino M, Hosoda Y, Okano M, Yasui M, and Kim Y
- Subjects
- Female, Gastrectomy, Humans, Middle Aged, Neoplasm Metastasis, Prognosis, Time Factors, Adenocarcinoma drug therapy, Adenocarcinoma secondary, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology
- Abstract
We report the case of a patient who underwent conversion surgery after long-term chemotherapy for advanced gastric carcinoma with synchronous distant metastasis. She was admitted to our hospital because of back pain and elevated serum ALP level. Gastrointestinal endoscopy showed multiple 0-Ⅱa like lesions at the gastric antrum, and a biopsy specimen showed poorly differentiated adenocarcinoma negative for HER2. Colonoscopy showed a submucosal tumor at the cecum, and pathological examination revealed metastatic gastric adenocarcinoma. CT revealed regional lymph node metastasis, bilateral ovarian tumors, and systemic bone absorption indicating metastasis. Systemic chemotherapy with cisplatin and S-1 was carried out, and complete resolution of gastric and colic lesions was obtained. Afterwards, a new gastric lesion appeared with re-growth of regional lymph nodes and bilateral ovarian tumors. Distal gastrectomy with D2 dissection and bilateral ovariectomy was performed 2 years 6 months after the initial therapy. Although systemic chemotherapy is the standard treatment for advanced gastric carcinoma with distant metastasis, surgical resection can be justified when drug-resistant lesions are localized and conversion surgery is feasible. Postoperative chemotherapy is mandatory to prolong survival.
- Published
- 2015
29. [A Case of Rectal Cancer Successfully Treated with Stereotactic Radiotherapy for Liver and Lung Metastases].
- Author
-
Hosoda Y, Kim Y, Nishino M, Okano M, Nagai K, Yasui M, and Tsujinaka T
- Subjects
- Aged, 80 and over, Colectomy, Hepatectomy, Humans, Liver Neoplasms surgery, Lung Neoplasms secondary, Male, Rectal Neoplasms surgery, Recurrence, Liver Neoplasms secondary, Lung Neoplasms radiotherapy, Rectal Neoplasms pathology
- Abstract
An 84-year-old patient underwent anterior resection for rectal cancer (RS, T4a, N2, M0, Stage Ⅲb), without adjuvant chemotherapy. Liver metastasis 30 mm in diameter was found in the S7/8 segment 2 years and 6 months after surgery, and segmentectomy of the liver was performed. One year after hepatectomy, lung metastasis 9 mm in diameter was detected in the right S1 lobe. The tumor enlarged after a 2-month follow-up period. We decided to apply stereotactic radiotherapy (50 Gy/10 Fr) to control the lesion. The tumor shrunk and became a scar after treatment. The patient was in good health without any recurrences 7 months after stereotactic radiotherapy. Surgical resection is an optimal method to control lung metastasis from colon cancer when operable; however, there are cases with no indication for surgery due to co-morbidities. Stereotactic radiotherapy can be an effective treatment for lung metastasis from colon cancer when surgery is contraindicated.
- Published
- 2015
30. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
- Author
-
Kim Y, Hosoda Y, Kakita N, Yamada Y, Yamasaki M, Nishino M, Okano M, Nagai K, Yasui M, and Tsujinaka T
- Subjects
- Carcinoma, Hepatocellular surgery, Combined Modality Therapy, Hepatectomy, Humans, Liver Neoplasms pathology, Liver Neoplasms surgery, Male, Middle Aged, Niacinamide therapeutic use, Sorafenib, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Niacinamide analogs & derivatives, Phenylurea Compounds therapeutic use
- Abstract
A 50-year-old man presented to our hospital with the chief complaint of right hypochondriac pain and a palpable tumor. Advanced hepatocellular carcinoma (HCC) and chronic hepatitis B infection were diagnosed and treated by twice-repeated transcatheterarterial chemoembolization (TACE) followed by administration of entecavir. Two months after the last TACE, alpha-fetoprotein(AFP)and protein induced by vitamin K absence or antagonistII (PIVKA-II) levels had elevated, and multiple small early enhancing nodules were detected on computed tomography(CT)scan. Based on his age and liver function (Child-Pugh score A5), a full dose of sorafenib (800 mg/day) was administered. The sorafenib dose was decreased after one month to 400mg/day because of hand-foot syndrome. Following sorafenib administration, the lesions shrank markedly, and complete response (CR) according to modified Response Evaluation Criteria In Solid Tumors(mRECIST)was achieved within 4 months. Six months after sorafenib treatment was begun, recurrent HCC was detected in segment 6, near the previously treated lesion. The decreased size of the main tumor and normalization of AFP levels allowed curative surgical resection. The patient was discharged 5 days after surgery and is currently treated with a half dose of sorafenib. Thirteen months after surgery, a small early enhancing lesion is visible on postoperative CT scan, but AFP and PIVKA-II levels are still keeping in a normal range. This case demonstrates that if sorafenib treatment is effective, then subsequent surgical treatment can be reconsidered in patients with advanced HCC responding to this combined therapy.
- Published
- 2014
31. [A case report of the use of laparoscopic surgery to remove an adrenal tumor following resection of sigmoid colon cancer].
- Author
-
Okano M, Yasui M, Nishino M, Hosoda Y, Nagai K, Kim Y, and Tsujinaka T
- Subjects
- Adrenal Gland Neoplasms secondary, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Capecitabine, Chemotherapy, Adjuvant, Deoxycytidine administration & dosage, Deoxycytidine analogs & derivatives, Female, Fluorouracil administration & dosage, Fluorouracil analogs & derivatives, Humans, Middle Aged, Multimodal Imaging, Organoplatinum Compounds administration & dosage, Oxaliplatin, Positron-Emission Tomography, Recurrence, Sigmoid Neoplasms surgery, Tomography, X-Ray Computed, Adrenal Gland Neoplasms surgery, Laparoscopy, Sigmoid Neoplasms pathology
- Abstract
A 58-year-old woman underwent sigmoidectomy and partial cystectomy for sigmoid colon cancer following colostomy. The final staging of the tumor was T3, N1, tub2, M0, fStage IIIa. She received 6 courses of CapeOX (oxaliplatin 130mg/m², capecitabine 200mg/m²) as adjuvant chemotherapy, which was discontinued because of severe general fatigue. At the same time, an increase in the levels of serum carcinoembryonic antigen (CEA) was detected and abdominal computed tomography (CT) revealed an expanded adrenal mass. Since whole-body ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) showed no evidence of multiple organ metastases except for the right adrenal tumor, a solitary adrenal metastasis from sigmoid colon cancer was strongly suspected. Hence, colostomy closure and laparoscopic adrenalectomy were concurrently performed. Histological examination revealed non-functional adrenal adenoma. Therefore, laparoscopic surgery was a reasonable choice even in this complex case.
- Published
- 2014
32. [Judgment of eradication of H. pylori based on percent changes in serum pepsinogens].
- Author
-
Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Sugimoto K, Osawa S, and Shirai N
- Subjects
- Helicobacter Infections blood, Humans, Pepsinogen C blood, Biomarkers blood, Helicobacter Infections microbiology, Helicobacter pylori isolation & purification, Pepsinogen A blood
- Published
- 2013
33. [Effects of preoperative oral carbohydrate administration on gastric contents].
- Author
-
Sato C, Shibuya H, Nishino M, Maeda A, Shimakawa N, and Okada T
- Subjects
- Adult, Aged, Female, Gastric Acidity Determination, Glucose metabolism, Humans, Hydrogen-Ion Concentration, Male, Middle Aged, Patient Satisfaction, Safety, Young Adult, Anesthesia, General, Dietary Carbohydrates administration & dosage, Gastrointestinal Contents chemistry, Preoperative Care
- Abstract
Background: Preoperative oral carbohydrate administration for adult patients has been recommended by European Society for Parenteral and Enteral Nutrition and Enhanced Recovery After Surgery. Although preoperative oral carbohydrate may improve patient satisfaction and perioperative glucose metabolism, its effects on the gastric contents remain controversial., Methods: We included 232 adult patients without gastrointestinal stenosis or occlusion. Seventy-four patients (group A) were not permitted to eat or drink before operation for eight hours, while 158 patients (group B) took oral carbohydrate (225 ml, 22.3% glucose) two hours before anesthesia induction. After induction, gastric contents were aspirated to examine its volume and pH., Results: Although the mean volume of gastric contents of the patients in group B was significantly lower than that in group A, and gastric pH was also significantly smaller in group B, no patients suffered from aspiration during rapid induction. Fasting interval and gastric volume were inversely related, and almost all the patients with fasting interval above 150 minutes showed gastric contents volume smaller than 25 ml and gastric pH more than 2.5., Conclusions: We conclude that preoperative oral carbohydrate can be given safely, although the fasting interval should be 150 minutes in our diet regimen.
- Published
- 2012
34. [Case report; a saved case of Legionella pneumonia by percutaneous cardiopulmonary support].
- Author
-
Terada H, Tamaki S, Shono T, Tatsuta H, Hoso T, Matsumoto M, Sakai S, Nishino M, and Yamamoto Y
- Subjects
- Disseminated Intravascular Coagulation etiology, Humans, Legionnaires' Disease complications, Male, Middle Aged, Respiratory Distress Syndrome etiology, Cardiopulmonary Resuscitation methods, Legionnaires' Disease therapy
- Published
- 2011
- Full Text
- View/download PDF
35. [Equalization of breast cancer chemotherapy at general hospital( II )-evaluation of safety in FEC and TC regimens].
- Author
-
Kitada N, Nishino M, Yasuda J, Morita S, Fujii C, Minegaki T, Kondoh M, Anami S, Takara K, and Watari M
- Subjects
- Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Blood Cell Count, Ciprofloxacin therapeutic use, Cyclophosphamide therapeutic use, Docetaxel, Epirubicin adverse effects, Epirubicin therapeutic use, Female, Fluorouracil adverse effects, Fluorouracil therapeutic use, Hospitals, General, Humans, Japan, Middle Aged, Neutropenia drug therapy, Taxoids therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms drug therapy, Cyclophosphamide adverse effects, Neutropenia chemically induced, Taxoids adverse effects
- Abstract
The safety of epirubicin (75 mg/m(2)), 5-fluorouracil (500 mg/m(2)) plus cyclophosphamide (500 mg/m(2)) (FEC75 therapy) and docetaxel (75 mg/m(2)) plus cyclophosphamide (600 mg/m(2)) (TC therapy) every three weeks as neoadjuvant or adjuvant chemotherapy was evaluated. Six or 9 patients received FEC75 or TC therapy, respectively. The nadir of white blood cells and neutrocyte counts in FEC75 and TC therapy were after 11-15 days and 8-11 days of chemotherapy, respectively. On the other hand, those of monocyte and reticulocyte counts were after 8-11 and 4-8 days for FEC75 and TC therapy, respectively. This suggests that there is a lag time in these parameters for the evaluation of myelosuppression in each chemotherapy regimen, resulting in the prediction of the degree of myelotoxicity by these profiles. Although 2 patients who received TC therapy encountered febrile neutropenia, the symptoms were improved by quinolones, and so granulocyte colony-stimulating factor was not needed. In addition, remarkable non-hematological side effects were not observed, and, therefore, almost all chemotherapy was performed as scheduled. From these results, FEC75 and TC therapy are considered to be safe.
- Published
- 2009
36. [A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation].
- Author
-
Osawa S, Yamada T, Iwaizumi M, Hamaya Y, Takagaki K, Nishino M, Kodaira C, Muramatsu A, Yoshida K, Sugimoto K, Futami H, Furuta T, and Ikuma M
- Subjects
- Adenocarcinoma diagnostic imaging, Adenocarcinoma pathology, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Combined Modality Therapy, Endoscopy, Gastrointestinal, Esophageal Neoplasms diagnostic imaging, Esophageal Neoplasms pathology, Fluorouracil administration & dosage, Humans, Infusions, Intravenous, Male, Organoplatinum Compounds administration & dosage, Radiography, Adenocarcinoma drug therapy, Adenocarcinoma radiotherapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Esophageal Neoplasms drug therapy, Esophageal Neoplasms radiotherapy, Fluorouracil therapeutic use, Organoplatinum Compounds therapeutic use
- Abstract
We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU. A 86-year-old man who had non-tuberculous mycobacterial infection was admitted for dysphagia, and diagnosed with Stage II A (T2N0M0) esophageal adenocarcinoma of the lower esophagus according to the TNM classification (sixth edition) of the International Union against Cancer (UICC). Chemoradiotherapy using daily low-dose CDGP and continuous infusion of 5- FU was performed, and thereafter one cycle of chemotherapy using CDGP and 5-FU was added. As the side effects of treatment, grade 3 leucopenia was observed while he was receiving chemoradiotherapy. A year later, he presented with grade 2 pericardial and pleural effusion and recovered with conservative treatment. CR was obtained and has been continued for two years. Definitive chemoradiotherapy using daily low-dose CDGP and continuous infusion of 5-FU is an effective choice for elderly and high-risk patients with esophageal adenocarcinoma.
- Published
- 2009
37. [Cyclic thrombocytopenia complicated with Sjögren syndrome and the mechanism of periodic platelet count fluctuation].
- Author
-
Yamauchi N, Muramatsu H, Inomata H, Numata T, Nozawa E, Nishino M, Koyama R, Ihara K, Nishisato T, Hirayama M, Katsuki S, Matsunaga T, and Niitsu Y
- Subjects
- Aged, Female, Humans, Immunoglobulin G blood, Prednisolone therapeutic use, Purpura, Thrombocytopenic, Idiopathic drug therapy, Purpura, Thrombocytopenic, Idiopathic immunology, Sjogren's Syndrome drug therapy, Stem Cells metabolism, Periodicity, Platelet Count, Purpura, Thrombocytopenic, Idiopathic blood, Purpura, Thrombocytopenic, Idiopathic etiology, Sjogren's Syndrome complications
- Abstract
Cyclic thrombocytopenia is a rare disorder with periodic changes of the platelet count. We experienced a patient with cyclic thrombocytopenia and Sjögren syndrome (SS), and studied the mechanism of the cyclic changes of the platelet count. The patient, a 75-year-old woman, was referred to our hospital because of dry mouth, dry eyes, and severe thrombocytopenia. Her platelet count varied from 0.2 x 10(4)/microl to 22.7 x 10(4)/microl in 14-28-day cycles. Anti-SS-A/Ro antibody and Schirmer's test were positive. Histological examination of the salivary glands revealed infiltration of inflammatory cells, leading to the diagnosis of SS. There was an inverse relation between the platelet count and serum levels of PA-IgG. When the platelet count was low, the number of bone marrow megakaryocytes and the colony counts of CFU-Meg decreased. The serum thrombopoietin level increased at the nadir of the platelet count and decreased as platelets increased. After prednisolone therapy, her platelet count increased along with the improvement of sicca symptoms. These findings suggest that platelet fluctuation is due to the periodic increase of platelet destruction, as well as periodic failure of platelet production.
- Published
- 2008
38. [Case of drug-induced pneumonitis associated with a dietary supplement containing CoQ10].
- Author
-
Nishino M, Usami M, Sugimura S, and Yoshizaki S
- Subjects
- Coenzymes, Female, Humans, Lymphocyte Activation, Middle Aged, Pneumonia diagnosis, Pneumonia drug therapy, Prednisolone administration & dosage, Pulmonary Eosinophilia diagnosis, Treatment Outcome, Ubiquinone adverse effects, Dietary Supplements adverse effects, Pneumonia chemically induced, Pulmonary Eosinophilia chemically induced, Ubiquinone analogs & derivatives
- Abstract
A 61-year-old woman began to take a dietary supplement contained CoQ10 and perilla leaf extract. Two months later, a dry cough appeared. The number of eosinophils in peripheral blood was elevated and chest radiograph images showed infiltrative shadows in the left middle lung. A chest CT scan showed consolidation in the left upper lobe (S3) and lower lobe (S10). The percentage of eosinophils was abnormally high in bronchoalveolar lavage fluid (BALF), and examination of a transbronchial lung biopsy (TBLB) specimen showed marked infiltration of eosinophils in the alveolar wall. Drug lymphocyte stimulation test (DLST) indicated high stimulation index for both supplement containing CoQ10 and its element of CoQ10. We diagnosed drug-induced pneumonitis, caused by CoQ10. The symptoms of the patient and pulmonary infiltrative shadows on chest radiograph improved after she stopped taking the supplements and started taking prednisolone orally. Recently various dietary supplements are coming onto the market. Since the possible adverse effects of these supplements are not investigated extensively, care should be taken for symptoms relating to food supplements.
- Published
- 2006
39. [Secondary hyperthyroidism].
- Author
-
Nishino M and Murakami M
- Subjects
- Diagnosis, Differential, Humans, Hyperthyroidism diagnosis, Hyperthyroidism physiopathology, Hyperthyroidism therapy, Pituitary Neoplasms complications, Pituitary Neoplasms diagnosis, Pituitary Neoplasms metabolism, Pituitary Neoplasms therapy, Prognosis, Thyroid Hormone Resistance Syndrome complications, Thyroid Hormone Resistance Syndrome diagnosis, Thyroid Hormone Resistance Syndrome therapy, Thyrotropin metabolism, Hyperthyroidism etiology
- Published
- 2006
40. [Iodine deficiency hypothyroidism].
- Author
-
Nishino M and Murakami M
- Subjects
- Animals, Humans, Hypothyroidism classification, Hypothyroidism therapy, Iodine administration & dosage, Thyroid Hormones biosynthesis, Hypothyroidism etiology, Iodine deficiency
- Published
- 2006
41. [A case report of autoimmune pancreatitis with Mikulicz' s disease and diabetes mellitus].
- Author
-
Takagi T, Doi T, Sakamoto H, Tatsuta H, Kobayashi Y, Tsubota Y, Nishino M, Nakano Y, Wakasaki H, Furuta H, and Nanjo K
- Subjects
- Diabetes Complications, Humans, Male, Middle Aged, Autoimmune Diseases complications, Mikulicz' Disease complications, Pancreatitis complications
- Abstract
A 56-year-old man with bilateral swelling of lacrimal glands was admitted to our hospital. He was diagnosed as autoimmune pancreatitis with Mikulicz' s disease presenting the swelling of lacrimal glands, submandibular glands and the pancreas head and tail. Treatment with systemic prednisolone resulted in improvement of the swelling of these glands and pancreas. On the immunohistochemical examination, infiltration of CD4- and CD8-positive T lymphocytes was detected in the lacrimal gland, the submandibular gland, the gall bladder and the pancreas. Infiltration of IgG4-positive plasma cells was detected in the submandibular gland, the gall bladder and the pancreas. These results may suggest the presence of common etiology between autoimmune pancreatitis and Mikulicz' s disease.
- Published
- 2006
42. [Thyroid peroxidase antibodies (TPOAb)].
- Author
-
Nishino M and Murakami M
- Subjects
- Biomarkers blood, Enzyme-Linked Immunosorbent Assay, Graves Disease diagnosis, Humans, Radioimmunoassay, Reference Values, Specimen Handling, Thyroid Function Tests, Thyroiditis, Autoimmune diagnosis, Autoantibodies blood, Iodide Peroxidase immunology
- Published
- 2005
43. [TSH (thyroid stimulating hormone)].
- Author
-
Nishino M and Murakami M
- Subjects
- Biomarkers blood, Diagnostic Techniques, Endocrine, Feedback, Physiological, Humans, Immunoenzyme Techniques, Immunoradiometric Assay, Luminescent Measurements, Pituitary Gland physiopathology, Reference Values, Specimen Handling, Thyroid Diseases diagnosis, Thyrotropin blood
- Published
- 2005
44. [Antithyroglobulin antibodies and antimicrosomal antibodies].
- Author
-
Nishino M and Murakami M
- Subjects
- Autoantibodies immunology, Biomarkers blood, Graves Disease diagnosis, Hemagglutination Tests methods, Humans, Radioimmunoassay methods, Reference Values, Specimen Handling, Thyroid Function Tests, Thyroid Neoplasms diagnosis, Thyroiditis, Autoimmune diagnosis, Autoantibodies blood, Microsomes immunology
- Published
- 2005
45. [Present status and necessity of cooperative countermeasures against biochemical terrorism by federal and regional governments and related agencies].
- Author
-
Nishino M and Shimazu T
- Subjects
- Humans, Japan, Physician's Role, United States, Bioterrorism prevention & control, Government, Government Agencies, Security Measures organization & administration
- Published
- 2003
46. [Examination of SUV of regional activity concentration for simultaneous emission/transmission acquisition using the mask technique].
- Author
-
Abe S, Nishino M, Yamashita M, and Yamaguchi H
- Subjects
- Fluorine Radioisotopes pharmacokinetics, Fluorodeoxyglucose F18 pharmacokinetics, Phantoms, Imaging, Radiopharmaceuticals pharmacokinetics, Tomography, Emission-Computed methods
- Abstract
To achieve quantitative accuracy of simultaneous emission/transmission (SET) acquisition using the mask technique, we determined the factor of expression that derives the true transmission data from the measured transmission and emission data. We then evaluated the standardized uptake value (SUV) of the regional activity concentration derived respectively from the SET scans and conventional scans. First, to determine the attenuation factor for the transmission source when the photons of the cylindrical phantom filled with (18)F solution reached emission memory, SET scans were performed with a dummy transmission source and under the blank status of the transmission source. Second, to evaluate the SUV, we used a hollow-sphere phantom filled with (18)F solution whose activity concentrations were approximately 3 and 5 times that of the background. Then we performed conventional and SET scans of the phantom for solutions ranging from the higher concentration to the lower concentration. All of the data were reconstructed with the decay correction, and the SUV of each sphere was derived. The results demonstrated that, when the conventional factor was used, SUV was underestimated according to the increasing activity concentration of the solution. However, when a new factor that took into account the attenuation of the transmission source was used, there was no significant difference in the SUV. We estimated the SUV derived from the SET scans was within 3% for the large spheres and within 16% for the small spheres.
- Published
- 2003
- Full Text
- View/download PDF
47. [A case of large-cell lung cancer with liver metastasis successfully treated using combination chemotherapy with CDDP and vinorelbine].
- Author
-
Katsuki S, Kitaoka K, Takizawa K, Machida T, Oku T, Sumiyoshi T, Nagamachi Y, Inomata H, Nojiri S, Nishino M, Fujita M, and Niitsu Y
- Subjects
- Adult, Carcinoma, Large Cell secondary, Cisplatin administration & dosage, Drug Administration Schedule, Female, Humans, Liver Neoplasms secondary, Lung Neoplasms pathology, Vinblastine administration & dosage, Vinorelbine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Large Cell drug therapy, Liver Neoplasms drug therapy, Lung Neoplasms drug therapy, Vinblastine analogs & derivatives
- Abstract
A 38-year-old woman presented to our hospital with the chief complaint of dyspnea. A chest radiograph showed pleural effusion of the right lung and a CT scan revealed liver metastasis. A tumor biopsy done under bronchoscopy revealed large-cell carcinoma of the lungs. She was given 4 courses of a combination therapy consisting of CDDP (80 mg/m2) and vinorelbine (25 mg/m2). The primary tumor in the right lung and liver metastasis were markedly reduced in size and a partial response was obtained. The combination therapy of CDDP and vinorelbine may become a standard chemotherapy for advanced non-small cell lung cancer.
- Published
- 2002
48. [Clinical usefulness of contrast-enhanced intracoronary ultrasound (ICUS) and evaluation of suitable contrast agents for ICUS].
- Author
-
Tanaka K, Nishino M, and Tanouchi J
- Subjects
- Albumins administration & dosage, Female, Humans, Iopamidol administration & dosage, Iopamidol analogs & derivatives, Ioxaglic Acid administration & dosage, Male, Microspheres, Middle Aged, Sodium Chloride, Sonication, Contrast Media administration & dosage, Coronary Vessels diagnostic imaging, Ultrasonography, Interventional methods
- Abstract
It is sometimes difficult to visualize the luminal borders of the vessel even by intracoronary ultrasound (ICUS), especially after coronary intervention. In this study, we evaluated the potential for improving visualization at intervention sites using contrast-enhanced ICUS and the suitable contrast agents for this procedure in humans. In 37 patients, ICUS (30 MHz) was performed with intracoronary injection (3 ml) of 7 different contrast preparations and without the contrast agents (control) after coronary intervention. The contrast agents used were as follows: saline solution, standard iomeprol, standard ioxaglate, sonicated iomeprol, sonicated ioxaglate, 50% Albunex, and 100% Albunex. Vessel wall delineation, contrast homogeneity (Grade 0-3), peak contrast intensity and shadowing were examined. Homogeneous and complete opacification of the vessel lumen and false lumen was observed with sonicated ioxaglate, 50% and 100% Albunex. Shadowing was not observed at all with sonicated ioxaglate and was uncommon with 50% Albunex, whereas 100% Albunex caused shadowing in all cases. The coronary delineation rate with the other contrast agents was only 50-70 %, and the homogeneity and peak intensity were relatively low. Thus, sonicated ioxaglate and 50 % Albunex both achieved good visualization, but the former is cheaper, stable and takes shorter to prepare. Large dissection in 5 patients were found by contrast-enhanced ICUS' whereas they were not detected by coronary angiography. All of them needed additional interventional therapy due to the results of contrast-enhanced ICUS. In conclusion, contrast-enhanced ICUS is useful for evaluation of the results by intervention therapy, and of the agents we studied sonicated ioxaglate is best for contrast-enhanced ICUS.
- Published
- 1998
49. [E 4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats].
- Author
-
Yamaguchi K, Oka M, Nishino M, Hanasato N, Kira S, and Fukuchi Y
- Subjects
- 3',5'-Cyclic-GMP Phosphodiesterases metabolism, Animals, Blood Pressure drug effects, Chronic Disease, Lung enzymology, Male, Phosphodiesterase Inhibitors pharmacology, Piperidines pharmacology, Pulmonary Artery physiopathology, Quinazolines pharmacology, Rats, Rats, Sprague-Dawley, Hypertension, Pulmonary drug therapy, Hypoxia drug therapy, Phosphodiesterase Inhibitors therapeutic use, Piperidines therapeutic use, Quinazolines therapeutic use, Vasodilator Agents therapeutic use
- Abstract
To test whether a potent cGMP-specific phosphodiesterase inhibitor, E 4021, is a selective pulmonary vasodilator in pulmonary hypertension, we studied its acute hemodynamic effects in conscious, chronically hypoxic pulmonary hypertensive rats. Chronically hypoxic pulmonary hypertension was induced by keeping adult Sprague-Dawley rats in a hypobaric chamber for 3 weeks. Two days after catheterization. E 4021 was injected intravenously at doses of 3, 10, 30, 100, 300, and 1,000 micrograms/kg at 10-min intervals. E 4021 caused significant decreases in mean pulmonary arterial pressure of 11 +/- 5, 12 +/- 6, and 18 +/- 5% at doses of 100, 300, and 1,000 micrograms/kg, respectively. In contrast to its depressor effect on mean pulmonary arterial pressure, E 4021 decreased mean systemic arterial pressure significantly (by 9 +/- 2%) at a dose of 1,000 micrograms/kg only. Heart rate and cardiac output were unchanged after the administration of E 4021. Tissue cGMP-specific phosphodiesterase activity was markedly higher in lung than in aorta. These results indicate that E 4021 is a relatively selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. We conclude E 4021 may be useful for the treatment of pulmonary hypertension.
- Published
- 1998
50. [Information on von Willebrand disease].
- Author
-
Nishino M and Fujimura Y
- Subjects
- Autoantigens blood, Collagen metabolism, Factor VIII metabolism, Humans, Platelet Glycoprotein GPIIb-IIIa Complex metabolism, Platelet Glycoprotein GPIb-IX Complex metabolism, Point Mutation, Reference Standards, von Willebrand Factor genetics, von Willebrand Factor immunology, von Willebrand Factor metabolism, von Willebrand Diseases classification, von Willebrand Diseases diagnosis
- Abstract
The revised classification of von Willebrand disease (VWD) was approved by the International Society of Thrombosis and Haemostasis (ISTH)/SSC in 1993. It consists of three major categories : quantitative defect in type 1, qualitative defect in type 2, and complete deficiency in type 3. Type 2 has four subtypes : decreased GPIb binding with deficient larger multimer of VWF in type 2A, excessive GPIb binding in type 2B, defective GPIb binding with larger multimer in type 2M, and defective FVIII binding in type 2N. Subsequently, criteria for diagnosis of VWD is being reconsidered by the association. Therefore, we introduced the guidelines for diagnosis of VWD type 1 and type 2N in our department.
- Published
- 1997
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.